What is the recommended dose of terbinafine (Lamisil) for treating onychomycosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended dose of terbinafine (Lamisil) for treating onychomycosis is 250 mg orally once daily, with treatment durations of 6 weeks for fingernail infections and 12–16 weeks for toenail infections. This recommendation is based on the British Association of Dermatologists' guidelines for the management of onychomycosis 2014 1, which suggests that terbinafine should be considered as the first choice for treating dermatophyte onychomycosis due to its higher efficacy and tolerability compared to itraconazole.

Key Considerations

  • Terbinafine is an allylamine antifungal that works by inhibiting squalene epoxidase, disrupting fungal cell membrane synthesis 1.
  • The medication can be taken with or without food and should be continued for the full prescribed duration, even if improvement is seen earlier, to prevent recurrence.
  • Patients should be aware that complete nail clearing may take several months after completing therapy as the healthy nail grows out.
  • Liver function tests are recommended before starting treatment due to the rare risk of hepatotoxicity 1.
  • Terbinafine is generally preferred over alternatives like itraconazole for dermatophyte nail infections because of its higher cure rates and fewer drug interactions 1.

Treatment Duration and Monitoring

  • For fingernail infections, the typical treatment duration is 6 weeks.
  • For toenail infections, the treatment duration is 12–16 weeks due to the slower growth rate of toenails and deeper fungal penetration.
  • Patients should be re-evaluated 3–6 months after treatment initiation, and further treatment should be given if the disease persists 1.

From the FDA Drug Label

DOSAGE AND ADMINISTRATION Fingernail onychomycosis: One 250 mg tablet, once daily for 6 weeks. Toenail onychomycosis: One 250 mg tablet, once daily for 12 weeks

The recommended dose of terbinafine (Lamisil) for treating onychomycosis is:

  • 250 mg once daily for 6 weeks for fingernail onychomycosis
  • 250 mg once daily for 12 weeks for toenail onychomycosis 2

From the Research

Recommended Dose of Terbinafine for Onychomycosis

The recommended dose of terbinafine (Lamisil) for treating onychomycosis is:

  • 250 mg/day for 12 or 16 weeks, as shown in studies 3, 4
  • Alternatively, a pulse regimen of 500 mg/day for 7 days every 3 months, totaling four treatments, has also been found to be effective 5
  • Another study suggests that a combination of oral terbinafine 250 mg/day for 12 weeks with ciclopirox nail lacquer topical solution, 8% may also be an effective treatment option 6

Efficacy of Terbinafine

The efficacy of terbinafine in treating onychomycosis has been demonstrated in several studies, with:

  • Mycologic cure rates ranging from 66.7% to 81% 3, 6, 7
  • Complete cure rates ranging from 35% to 42% 3, 7
  • Clinical cure rates ranging from 40% to 46% 3, 6

Safety and Tolerability

Terbinafine has been found to be generally well-tolerated, with:

  • Adverse events experienced by 10.5% of patients 3
  • Most common adverse events being gastrointestinal complaints 3
  • A low potential for drug-drug interactions 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.